These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1528 related items for PubMed ID: 16230475

  • 21. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta.
    Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P.
    J Immunol; 2010 May 15; 184(10):5885-94. PubMed ID: 20382885
    [Abstract] [Full Text] [Related]

  • 22. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH.
    Nat Immunol; 2000 Aug 15; 1(2):119-26. PubMed ID: 11248803
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells.
    Roncarolo MG, Gregori S, Levings M.
    Novartis Found Symp; 2003 Aug 15; 252():115-27; discussion 127-31, 203-10. PubMed ID: 14609215
    [Abstract] [Full Text] [Related]

  • 25. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
    Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP.
    Cancer Res; 2005 Sep 15; 65(18):8479-86. PubMed ID: 16166328
    [Abstract] [Full Text] [Related]

  • 26. NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells.
    Fausther-Bovendo H, Wauquier N, Cherfils-Vicini J, Cremer I, Debré P, Vieillard V.
    AIDS; 2008 Jan 11; 22(2):217-26. PubMed ID: 18097224
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T, Barber A, Sentman CL.
    Cancer Res; 2006 Jun 01; 66(11):5927-33. PubMed ID: 16740733
    [Abstract] [Full Text] [Related]

  • 30. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT.
    J Clin Invest; 1993 Dec 01; 92(6):2569-76. PubMed ID: 7504687
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
    Zhang C, Zhang J, Niu J, Zhou Z, Zhang J, Tian Z.
    Hum Immunol; 2008 Aug 01; 69(8):490-500. PubMed ID: 18619507
    [Abstract] [Full Text] [Related]

  • 33. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
    André P, Castriconi R, Espéli M, Anfossi N, Juarez T, Hue S, Conway H, Romagné F, Dondero A, Nanni M, Caillat-Zucman S, Raulet DH, Bottino C, Vivier E, Moretta A, Paul P.
    Eur J Immunol; 2004 Apr 01; 34(4):961-71. PubMed ID: 15048706
    [Abstract] [Full Text] [Related]

  • 34. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
    Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z.
    Cancer Res; 2007 Aug 01; 67(15):7458-66. PubMed ID: 17671216
    [Abstract] [Full Text] [Related]

  • 35. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells.
    Bergmann C, Wild CA, Narwan M, Lotfi R, Lang S, Brandau S.
    Eur J Immunol; 2011 Dec 01; 41(12):3564-73. PubMed ID: 21905023
    [Abstract] [Full Text] [Related]

  • 36. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
    Zhang C, Zhang J, Wei H, Tian Z.
    Int Immunopharmacol; 2005 Jul 01; 5(7-8):1099-111. PubMed ID: 15914316
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
    Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M.
    Cancer Res; 2003 Dec 15; 63(24):8996-9006. PubMed ID: 14695218
    [Abstract] [Full Text] [Related]

  • 39. Requirements for control of B-cell lymphoma by NK cells.
    Brenner CD, King S, Przewoznik M, Wolters I, Adam C, Bornkamm GW, Busch DH, Röcken M, Mocikat R.
    Eur J Immunol; 2010 Feb 15; 40(2):494-504. PubMed ID: 19950185
    [Abstract] [Full Text] [Related]

  • 40. gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria.
    D'Ombrain MC, Hansen DS, Simpson KM, Schofield L.
    Eur J Immunol; 2007 Jul 15; 37(7):1864-73. PubMed ID: 17557374
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 77.